The number needed to treat to prevent a MACE event was 53 over 3.8 years
While research is still evolving, many people are exploring peptide therapy as part of a broader approach to mobility, recovery, and long-term joint health
Key post hoc analysis of the landmark Steno-2 trial showing that intensified, multifactorial treatment slows progression of diabetic nephropathy and renal function loss in microalbuminuric patients with T2DM
A few things make GHK-Cu unusual among peptide therapies: In plain language: GHK-Cu is one of your body's natural "repair signals," and replenishing it may help restore the regenerative signaling that quietly weakens over time
Dysfunctional adipose tissue promotes increased cardiovascular and diabetes disease risk via multiple pathways including increased free fatty acids (FFA) in the liver, infiltration of visceral fat deposits by proinflammatory macrophages resulting in chronic low-grade inflammation, and reduced buffering capacity for protective lipid storage [7]
And what really frustrates people is that GLP-1 is something the body already makes, but companies tweak it just enough to patent it and then act like they own it ***Theres no reason one company should control a natural hormone just because they made a small modification